Suppr超能文献

体外膜肺氧合在 2009 年甲型 H1N1 流感大流行中的应用。

Extracorporeal membrane oxygenation in the context of the 2009 H1N1 influenza A pandemic.

机构信息

Division of Acute Care Surgery, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

Surg Infect (Larchmt). 2011 Apr;12(2):151-8. doi: 10.1089/sur.2010.082.

Abstract

BACKGROUND

Extracorporeal membrane oxygenation (ECMO) incorporates surgical techniques as adjuncts in the management of refractory respiratory dysfunction. For many years, its primary application was for support of neonatal infants in cardiorespiratory failure. As the 2009 H1N1 influenza A pandemic developed, more reports came in of severe respiratory dysfunction and even death that seemed to be occurring preferentially in younger adults. Centers with the capability began to use ECMO to salvage these patients.

RESULTS

The H1N1 virus is a subtype of influenza A. The hemagglutinin receptor binding is similar to that of the seasonal influenza virus, but 2009 H1N1 also binds to α2,3-linked receptors, which are found in the conjunctivae, distal airways, and alveolar pneumocytes. Influenza viruses elude host immune responses through drift and shift in the hemagglutinin (HA) and neuraminidase (NA) proteins. The incubation period ranges from 1-7 days. The majority of patients present with fever and cough, but a broad spectrum of clinical syndromes has been reported, and laboratory testing remains the mainstay of diagnosis. Most patients recover within a week without treatment. The H1N1 virus remains largely sensitive to the NA inhibitors but is resistant to the matrix protein-2 inhibitors. Extracorporeal membrane oxygenation provides continuous pulmonary (and sometimes cardiac) support and minimizes ventilator-induced lung injury. The potential for life-threatening complications is high. In 2009, in the Conventional Ventilation or ECMO for Severe Adult Respiratory Failure (CESAR) randomized trial of ECMO, the overall survival rate was 63% in the ECMO group compared with 47% in the control group (p = 0.03). Similar studies have been reported from Australia and New Zealand, Canada, and France.

CONCLUSIONS

Supportive management is continued along with ECMO. Antiviral drugs and antimicrobial agents should be given as appropriate, as should nutritional support. Volume management should be used. Ventilator settings should be reduced as ECMO support allows, with a goal of reducing airway pressures, ventilator rate, and FiO(2). Complications of ECMO are common. Bleeding, the most common, can result in death, especially if it occurs intracranially.

摘要

背景

体外膜肺氧合(ECMO)将外科技术作为治疗难治性呼吸功能障碍的辅助手段。多年来,它的主要应用是支持心肺衰竭的新生儿。随着 2009 年 H1N1 甲型流感大流行的发展,越来越多的报告表明严重的呼吸功能障碍甚至死亡似乎更优先发生在年轻成年人中。有能力的中心开始使用 ECMO 来抢救这些患者。

结果

H1N1 病毒是甲型流感的一个亚型。血凝素受体结合与季节性流感病毒相似,但 2009 年 H1N1 也与存在于结膜、远端气道和肺泡上皮细胞的α2,3 连接的受体结合。流感病毒通过血凝素(HA)和神经氨酸酶(NA)蛋白的漂移和转变来逃避宿主免疫反应。潜伏期为 1-7 天。大多数患者表现为发热和咳嗽,但已报告了广泛的临床综合征,实验室检测仍然是诊断的主要依据。大多数患者未经治疗在一周内康复。H1N1 病毒对 NA 抑制剂仍基本敏感,但对基质蛋白-2 抑制剂有耐药性。体外膜肺氧合提供持续的肺(有时是心脏)支持,并最大限度地减少呼吸机引起的肺损伤。发生危及生命的并发症的可能性很高。在 2009 年的常规通气或 ECMO 治疗严重成人呼吸衰竭(CESAR)ECMO 随机试验中,ECMO 组的总体生存率为 63%,而对照组为 47%(p=0.03)。来自澳大利亚和新西兰、加拿大和法国的类似研究也有报道。

结论

继续进行支持性治疗,同时进行 ECMO。应根据需要给予抗病毒药物和抗菌药物以及营养支持。应使用容量管理。随着 ECMO 支持允许,应降低呼吸机设置,目标是降低气道压力、呼吸机频率和 FiO(2)。ECMO 的并发症很常见。最常见的出血会导致死亡,尤其是颅内出血。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验